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pidemiology and prevention of meningococcal disease: a crit-
cal appraisal of vaccine policies
. McIntosh1,∗, M. Safadi2
Novartis Vaccines and Diagnostics, Amsterdam, Netherlands
Faculdade de Ciencias Medicas, Sao Paulo, Brazil
Background: Meningococcal disease is characterized by a
arked variation in incidence and serogroup distribution by region
nd over time. In several European countries, Canada andAustralia,
mmunization programs, including universal vaccination of infants
r toddlers, with catch-up campaigns in children and adolescents,
imed at controlling disease caused bymeningococcal serogroup C,
ave been successful in reducing disease incidence through direct
nd indirect protection. More recently, meningococcal conjugate
accines targeting disease caused by serogroups A, C, W135 and Y
ave been licensed and are being used in adolescent programs in
he USA and Canada. Also, a mass immunization campaign against
erogroup A disease has been implemented in Africa.
Methods: We gathered published information about meningo-
occal epidemiology and vaccination policy as well as deducing
accination policy decisions from an observation of how meningo-
occal vaccines are used in different situations.
Results: The policy options available for control ofmeningococ-
al infection are: routine age-speciﬁc recommendations; routine
nfant strategy plus catch-up (eg UK, Spain, Iceland, Portugal); rou-
ine toddler strategy plus catch-up (eg Australia, The Netherlands,
elgium, France, most of Canada); adolescent-only strategy (USA
nd Manitoba). Outbreak control policies have been used with suc-
ess in the African meningitis belt countries, New Zealand, Norway
nd Normandy. Policies to prevent travel-associated disease (eg
ajj and Amrah) have also been adopted in various parts of the
orld. The prevailing serogroup epidemiology determines the use
f monovalent versus multivalent vaccines and decisions on the
chedule can be affected by the potential for herd protection.
Conclusion: Enhanced surveillance including the use of sensi-
ive molecular techniques and capture/recapture, along with the
vailability of existing and new meningococcal vaccines, for exam-
le against serogroup B, allow for both improved policy decisions
nd more impactful reductions in the global burden of meningo-
occal infection.
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Economic evidence for policy makers in Vietnam: dengue fever
economic burden of disease and household willingness to pay
for dengue vaccines
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Anh2, L. Da Silva4
1 International Vaccine Institute, Seoul, Korea, Republic of
2 National Institute of Hygiene and Epidemiology, Hanoi, Viet Nam
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4 Novartis Vaccines and Diagnostics, Cambridge, MA, USA
Background:Dengue infection is amajor public health problem
in Vietnam where high incidence and repeated large outbreaks are
reported [7]. The knowledge on dengue cost of illness is limited
in Vietnam; while, the private demand for future dengue vaccines
is not studied which are essential for decision making on dengue
prevention, control and introduction of future vaccines.
Methods: We are conducting a comprehensive economic study
composed of a set of three surveys for estimating cost-of-illness
(COI); healthcare utilization; and willingness-to-pay (WTP) for
future dengue vaccine in Nha Trang, Vietnam. The COI study
will estimate cost of treating 200 conﬁrmed dengue cases which
includes direct costs for medicines, diagnostics, health service
delivery, and transport; as well as indirect cost due to productiv-
ity loss among patients and care takers. A questionnaire will be
administered to 400 participants to estimate private willingness
to pay for hypothetical vaccines against dengue infection where
they will be oriented about future dengue vaccine, presented with
one of ﬁve randomly assigned prices and asked howmany vaccines
they would purchase for the household and who would receive the
vaccine. A questionnaire will be used for assessing health seeking
behavior of the population for dengue cases.
Results: The COI survey was launched in Khanh Hoa General
Hospital (KHGH) in Nha Trang on the 1st of Nov., 2011 and a total of
13 dengue-conﬁrmed hospitalized patients and 2 outpatients have
been recruited thus far. Preliminary analysis showed that the pri-
vate direct out-of-pocket cost per hospitalized dengue case is fairly
high in Nha Trang (VND 2.5 million; US$125). Cost of illness can
be estimated once more cases are recruited. Focus group discus-
sions and a pilot test (44 household interviews) were conducted
prior to WTP survey. Most respondents (82%) understood about
proposed future dengue vaccine. Price points in the questionnaire
were determined based on the pilot test and questionnaire is being
ﬁnalized.
Conclusion: Once the sample size is achieved, we will calculate
direct and indirect cost-of-illness of the dengue-conﬁrmed cases
that sought care at the facility. Affordable vaccine price for public
andprivatedemand forup-comingdenguevaccinewill beassessed.
http://dx.doi.org/10.1016/j.ijid.2012.05.1005
